Canine Parvovirus Antibody Research Articles

Supplemental Dietary Selenohomolanthionine Improve Antioxidant Activity and Immune Function in Weaned Beagle Puppies.

The purpose of this study was to investigate the effects of dietary Selenohomolanthionine (SeHLan) on antioxidant status and immune response in canine parvovirus (CPV) vaccinated puppies. In this study, 30 weaned puppies were randomly divided into six groups: control group (–Se/–Vacc), immunization group (–Se/+Vacc), supplementation of sodium selenite group (SS/+Vacc, 0.35 mg/kg DM), low-dose SeHLan group (SeHLan-L/+Vacc, 0.35 mg/kg DM), mid-dose SeHLan group (SeHLan-M/+Vacc, 1.0 mg/kg DM), and high-dose SeHLan group (SeHLan-H/+Vacc, 2.0 mg/kg DM). The puppies were fed for 42 days and vaccinated with Vanguard Plus 5 on day 0 and day 21. Blood samples were collected on 7, 14, 21, 28, 35, 42 days post-immunization (PI) for determination of antioxidant indicators, lymphocyte proliferation index, serum cytokine concentration (IL-2, IL-4), canine polymorphonuclear neutrophils (PMN) phagocytic function, and the level of CPV antibody titers. The results showed that SeHLan supplementation raised the serum Se concentration and glutathione peroxidase (GSH-Px) activity in a dose-dependent manner (P < 0.05). It also increased the activity of serum superoxide dismutase (SOD) and decreased serum malondialdehyde (MDA) content, especially in SeHLan-M/+Vacc group (1.0 mg/kg DM) (P < 0.01). SeHLan supplementation significantly increased lymphocyte proliferation, IL-2, and IL-4 levels in canine serum, and enhanced phagocytosis of PMN in vaccinated puppies (P < 0.05). Moreover, SeHLan supplementation shortened the CPV antibody production time and increased the CPV antibody titers (P < 0.05). Of note, the beneficial effects of SeHLan were superior to those of SS. In conclusion, dietary SeHLan supplementation improved antioxidant activity, increased CPV antibody titers, and enhanced immune function in puppies after weaning. An appropriate dosage of SeHLan (1~2 mg/kg DM) may confer nutritional benefits in puppies.

Discrepancy Between In-clinic and Haemagglutination-Inhibition Tests in Detecting Maternally-Derived Antibodies Against Canine Parvovirus in Puppies.

Canine parvovirus (CPV) is one of the most common causes of mortality in puppies worldwide. Protection against CPV infection is based on vaccination, but maternally-derived antibodies (MDA) can interfere with vaccination. The aim of this study was to evaluate the applicability of an in-clinic ELISA test to assess the CPV MDA in unvaccinated puppies and CPV antibodies in bitches, comparing the results with the gold standard haemagglutination inhibition (HI) test. Serum samples of 136 unvaccinated puppies were tested, along with sera of 16 vaccinated bitches. Five unvaccinated puppies were retested after vaccination. Both assays showed that the 16 vaccinated bitches had protective antibody levels against CPV. Conversely, significant discrepancies were observed for the MDA titers in unvaccinated puppies. Protective MDA titers were observed in 91.9% puppies using HI and in 40.4% by the in-clinic ELISA test, and only the latter one showed a decrease of MDA titers and percentages of protected puppies after the first weeks of age. Vaccination of five puppies with high HI and low in-clinic ELISA MDA titers resulted in seroconversion. Our results confirm the reliability of the in-clinic ELISA test in determining protective antibodies against CPV in adult dogs. Our findings also suggest that the in-clinic ELISA test kit may also be a useful tool to detect and quantify CPV MDA, thus allowing prediction of the best time to vaccinate puppies and reduction of the rate of vaccination failures due to interference by maternally-derived antibodies.

Comparative immune responses of pups following modified live virus vaccinations against canine parvovirus.

Background and Aim:Canine parvovirus (CPV) is the most important viral cause of enteritis and mortality in pups. Evaluation and monitoring of pre- and post-vaccine immune responses may help to determine the efficacy of the current vaccination schedule being followed in pups in India. This study aimed to evaluate and monitor the pre- and post-vaccine immune responses of CPV vaccinated pups using hemagglutination inhibition (HI) assay. The neutralizing antibody titer levels were also detected using serum neutralization test (SNT).Materials and Methods:The pups were categorized into two groups, the double booster and the single booster groups. In this study, serum samples were subjected to HI and SNT for measuring the CPV antibody titer at frequent intervals for up to 6 months from 27 healthy pups following primary and booster CPV vaccinations.Results:The antibody titers in double booster pups reached their peaks at the 21st day after the second booster vaccination with a geometric mean (GM) of 3.57. The antibody titers in single booster pups reached their peaks at the 21st day after the first booster vaccination with a lower GM of 3.18.Conclusion:The double booster pups maintained a higher immune response throughout the period of the study compared to single booster pups though the difference in titers was not statistically significant. SNT results indicated that the raised antibody titer was also able to yield virus-neutralizing antibodies. No interfering maternally derived antibodies were found in the pups at the age of primary vaccination (45th day) in our study. Therefore, the second booster vaccination may be useful in maintaining the protective titer for a prolonged period.

Evaluation of a Community’s Risk for Canine Parvovirus and Distemper Using Antibody Testing and GIS Mapping of Animal Shelter Intakes

ABSTRACTThis cross-sectional study aimed to identify where dogs with negative antibody tests to canine parvovirus (CPV) and canine distemper virus (CDV) originated when entering a community shelter, using a commercially available ELISA antibody test and Geographic Information Systems mapping. Of 2745 canines entering during a three-month period, 1056 test results were obtained. Dogs or puppies weighing over 2 lb were eligible if they could be humanely, nonchemically restrained for phlebotomy. Age and minor health issues weren't exclusions. Dogs were excluded if trained personnel were concerned health would be compromised by phlebotomy. Blood samples were collected within 24 hours of entry. Four hundred and twenty-seven (40%) dogs had positive antibody test results for both viruses, 422 (40%) were positive for CPV, 37 (4%) were positive for CDV, and 170 (16%) were negative for both. Mapping revealed geographic patterns for dogs with negative antibody tests. This shelter admitted dogs with negative CPV and/or CDV antibody tests from defined community areas. Targeting vaccination efforts in communities to areas where dogs with negative antibody tests originate could be an effective wellness strategy.

Prevalence of antibodies to canine parvovirus and reaction to vaccination in client-owned, healthy dogs

The purpose of this population-based cohort study was to assess current prevalence of antibodies to canine parvovirus (CPV) in adult, healthy dogs, including risk factors associated with lack of antibodies,...

Influence of clinical and laboratory variables on faecal antigen ELISA results in dogs with canine parvovirus infection

False negative faecal canine parvovirus (CPV) antigen ELISA results in dogs with CPV infection are common, but the factors that lead to these false negative results are still unknown. The aim of this study was to investigate whether dogs with a false negative faecal CPV antigen ELISA result have milder clinical signs and laboratory changes, a lower faecal virus load, higher faecal and serum CPV antibody titres and a faster recovery than dogs with a positive result. Eighty dogs with CPV infection, confirmed by the presence of clinical signs and a positive faecal CPV polymerase chain reaction (PCR), were assigned to two groups according to their faecal antigen ELISA result. Time until presentation, severity of symptoms, laboratory parameters, faecal virus load, faecal and serum antibody titres, and CPV sequencing data were compared between both groups. In 38/80 dogs that were hospitalised until recovery, the time to recovery, mortality, and the course of the disease were compared between dogs with positive and negative faecal antigen ELISA results.Of the 80 dogs included, 41 (51.3%) had a false negative faecal antigen ELISA result. ELISA-negative dogs had a significantly shorter time until presentation, lower frequency of defaecation, lower faecal virus load, and higher serum antibody concentrations than ELISA-positive dogs. Laboratory changes, CPV shedding, and outcomes were not associated with faecal antigen ELISA results. In conclusion, low faecal CPV load and antibodies binding to CPV antigen in faeces are likely to be important reasons for false negative faecal antigen ELISA results. Dogs with clinical signs of CPV infection should be retested by faecal PCR.

An Infectious Disease and Mortality Survey in a Population of Free-Ranging African Wild Dogs and Sympatric Domestic Dogs

Disease can cause declines in wildlife populations and significantly threaten their survival. Recent expansion of human and domestic animal populations has made wildlife more susceptible to transmission of pathogens from domestic animal hosts. We conducted a pathogen surveillance and mortality survey for the population of African wild dogs (Lycaon pictus) in KwaZulu-Natal (KZN), South Africa, from January 2006–February 2007. Samples were obtained from 24 wild dogs for canine distemper virus (CDV) and canine parvovirus (CPV) serological testing. Data were collected on the presence of CDV, CPV, and rabies virus in the KZN domestic dog (Canis familiaris) population from 2004–06. The presence of these pathogens was confirmed in domestic dogs throughout KZN. Wild dogs exhibited 0% and 4.2% prevalence for CDV and CPV antibodies, respectively. In 2006 the largest wild dog pack in KZN was reduced from 26 individuals to a single animal; disease due to rabies virus was considered the most probable cause. This study provides evidence that CDV, CPV and rabies are potential threats to African wild dog conservation in KZN. The most economical and practical way to protect wild dogs from canine pathogens may be via vaccination of sympatric domestic dogs; however, such programmes are currently limited.

English

&nbsp; By removing the N-terminal hydrophobic sequence, truncated VP2 (tVP2) genes were cloned into the pET-32a (+) plasmid and subsequently expressed as His fusion proteins. The purified recombinant tVP2 proteins were specific to canine parvovirus (CPV), and one of them was used in an indirect enzyme-linked immunosorbent assay (ELISA) for the detection of CPV antibodies. The minimum detection limit of this method was 1:1280. There was good agreement between tVP2-based indirect ELISA and the commercially available diagnostic kit. The results suggest that the recombinant tVP2 protein-based ELISA could be used to detect CPV antibodies. Key words:&nbsp;Canine parvovirus, recombinant truncated VP2 (tVP2), enzyme-linked immunosorbent assay (ELISA), antibody detection

Accuracy of a point-of-care ELISA test kit for predicting the presence of protective canine parvovirus and canine distemper virus antibody concentrations in dogs

Canine parvovirus (CPV) and canine distemper virus (CDV) are highly infectious and often fatal diseases with worldwide distributions, and are important population management considerations in animal shelters. A point-of-care ELISA test kit is available to detect serum antibodies to CPV and CDV, and presumptively to predict protective status. The aim of this study was to determine the diagnostic accuracy of the test compared to CPV hemagglutination inhibition titers and CDV serum neutralization titers determined by a reference laboratory, using sera collected from dogs housed at animal shelters. The ELISA test was used under both field and laboratory conditions and duplicate specimens were processed using an extra wash step. The test kit yielded accurate results (CPV: sensitivity 92.3%, specificity 93.5%; CDV: sensitivity 75.7%, specificity 91.8%) under field conditions. CDV sensitivity was improved by performing the test under laboratory conditions and using an optical density (OD) meter (laboratory performed 94.0%; OD 88.1%). Point-of-care ELISA testing for serum CPV and CDV antibody titers was demonstrated to be a useful tool for determining antibody status when making decisions regarding the need for CPV and/or CDV vaccination and also in animal shelters for population management.

Serosurvey of selected viruses in captive giant pandas (Ailuropoda melanoleuca) in China

Serum samples from 92 giant pandas in three captive facilities were tested for antibodies against five viruses of carnivores. Antibody titers against canine distemper virus (CDV) in two facilities in which giant pandas were vaccinated were variable. The canine adenovirus (CAV-1) and canine parvovirus (CPV) titers in vaccinated group were both positive, but titers were not high and varied among individual except one vaccinated panda had extremely high CAV-1 titer, indicating infection with the field virus following vaccination. Our results suggest that the vaccines used for these giant pandas do not elicit consistent antibody titers. Antibody titers against CDV, CPV and CAV-1 in unvaccinated giant pandas were highly variable, especially CPV titer. Almost half of sera were CPV antibody positive, and CPV titers were high enough to suggest infection with the virus. Canine coronavirus (CCV) and canine parainfluenza virus (CPIV) titers were not detected in all serum samples. The results of this study emphasize the need for research on infectious diseases of giant pandas and development of suitable vaccines for the species.

Serologic Survey for Canine Distemper Virus and Canine Parvovirus in Free-ranging Wild Carnivores from Portugal

A serologic survey for Canine distemper virus (CDV) and canine parvovirus (CPV) was performed on serum and lung extract from an opportunistic sample of 120 free-ranging wild carnivores (13 species) from Portugal, collected from 1995 to 2006. Antibodies to CDV were detected in wolf (Canis lupus; 3/27) and red fox (Vulpes vulpes; 2/22). Antibodies to CPV were detected in wolf (9/28), red fox (2/14), wildcat (Felis silvestris;1/8), genet (Genetta genetta; 17/18), and stone marten (Martes foina; 3/17). Antibodies to CPV were detected throughout the study, whereas for CDV antibodies were detected in 3 of 10 yr and only during winter. The extremely high CPV antibody prevalence in genets is unprecedented. Although based on a limited sample, these data suggest widespread exposure of free-ranging Iberian carnivores to CDV and CPV.

DEMOGRAPHIC EFFECTS OF CANINE PARVOVIRUS ON A FREE-RANGING WOLF POPULATION OVER 30 YEARS

We followed the course of canine parvovirus (CPV) antibody prevalence in a subpopulation of wolves (Canis lupus) in northeastern Minnesota from 1973, when antibodies were first detected, through 2004. Annual early pup survival was reduced by 70%, and wolf population change was related to CPV antibody prevalence. In the greater Minnesota population of 3,000 wolves, pup survival was reduced by 40-60%. This reduction limited the Minnesota wolf population rate of increase to about 4% per year compared with increases of 16-58% in other populations. Because it is young wolves that disperse, reduced pup survival may have caused reduced dispersal and reduced recolonization of new range in Minnesota.

One-Step Immunochromatography Assay Kit for Detecting Antibodies to Canine Parvovirus

This study was performed to determine the feasibility of using whole serum to detect antibodies to canine parvovirus (CPV) under nonlaboratory conditions and to evaluate the performance characteristics of an immunochromatography assay kit. Precise detection of levels of antibody against CPV in puppies can be used to determine a vaccination schedule, because maternal antibodies frequently result in the failure of protective vaccination, and can also be used to determine the antibody levels of infected puppies. Several methods for the titration of CPV antibodies have been reported, including the hemagglutination inhibition (HI) assay, which is considered the "gold standard." These methods, however, require intricate and time-consuming procedures. In this study, a total of 386 serum specimens were tested. Compared to the HI assay, the rapid assay had a 97.1% sensitivity and a 76.6% specificity (with a cutoff HI titer of 1:80). This single-step assay could be performed rapidly and easily without special equipment. The kit provides a reliable method for detection of anti-CPV antibody where laboratory support and personnel are limited.

Clinical use of serum parvovirus and distemper virus antibody titers for determining revaccination strategies in healthy dogs

To assess whether serum canine parvovirus (CPV) and canine distemper virus (CDV) antibody titers can be used to determine revaccination protocols in healthy dogs. Case series. 1,441 dogs between 6 weeks and 17 years old. CPV and CDV antibody titers in serum samples submitted to a commercial diagnostic laboratory were measured by use of indirect fluorescent antibody (IFA) tests. On the basis of parallel measurements of CPV and CDV serum antibody titers in 61 paired serum samples determined by use of hemagglutination inhibition and serum neutralization methods, respectively, we considered titers > or = 1:5 (IFA test) indicative of an adequate antibody response. Age, breed, and sex were not significantly associated with adequate CPV- or CDV-specific antibody responses. Of 1,441 dogs, 1,370 (95.1%) had adequate and 71 (4.9%) had inadequate antibody responses to CPV, whereas 1,346 of 1,379 (97.6%) dogs had adequate and 33 (2.4%) had inadequate responses to CDV. Vaccination histories were available for 468 dogs (468 for CPV, 457 for CDV). Interval between last vaccination and antibody measurement was 1 to 2 years for the majority (281/468; 60.0%) of dogs and 2 to 7 years for 142 of 468 (30.3%) dogs. Interval was < 1 year in only 45 of 468 (9.6%) dogs. The high prevalence of adequate antibody responses (CPV, 95.1%; CDV, 97.6%) in this large population of dogs suggests that annual revaccination against CPV and CDV may not be necessary.

Disease as a threat to endangered species: Ethiopian wolves, domestic dogs and canine pathogens

With increasing awareness of disease as an endangering process, an assessment of which pathogens might pose a problem and their patterns of infection in natural hosts is necessary. This paper examines the exposure of sympatric Ethiopian wolves (Canis simensis) and domestic dogs to canine distemper virus (CDV), canine adenovirus (CAV) and canine parvovirus (CPV) in the Bale region, Ethiopia and then relates these data to population trends of wolves. Wolves (n= 30) sampled between 1989 and 1992 had been exposed to CDV, CAV and CPV, but only CAV might be able to persist in this wolf population. Anecdotal and serological evidence suggested that an epidemic of CDV occurred in the dog population of the Bale Mountains National Park (BMNP) in 1992–93. All park dogs born since this time were seronegative to CDV, although some young dogs in the nearby urban population were seropositive. Despite evidence of CAV infection in wolves, none of the dogs sampled in the park were CAV seropositive, although this virus appeared highly seroprevalent and endemic in urban dogs. All dogs tested for CPV antibodies were seropositive. The BMNP wolf population declined in the late 1980s and early 1990s, with rabies responsible for a dramatic population reduction between 1990 and 1992. Although the population declined further up until 1995, it is not possible to assess whether the concurrent canine distemper epidemic in park dogs also affected wolves. Nevertheless, with evidence of rabies, CDV, CAV and CPV infections in sympatric domestic dogs and Ethiopian wolves, canid diseases clearly pose a significant threat to the future persistence of this Ethiopian wolf population.

Disease as a threat to endangered species: Ethiopian wolves, domestic dogs and canine pathogens

AbstractWith increasing awareness of disease as an endangering process, an assessment of which pathogens might pose a problem and their patterns of infection in natural hosts is necessary. This paper examines the exposure of sympatric Ethiopian wolves (Canis simensis) and domestic dogs to canine distemper virus (CDV), canine adenovirus (CAV) and canine parvovirus (CPV) in the Bale region, Ethiopia and then relates these data to population trends of wolves. Wolves (n= 30) sampled between 1989 and 1992 had been exposed to CDV, CAV and CPV, but only CAV might be able to persist in this wolf population. Anecdotal and serological evidence suggested that an epidemic of CDV occurred in the dog population of the Bale Mountains National Park (BMNP) in 1992–93. All park dogs born since this time were seronegative to CDV, although some young dogs in the nearby urban population were seropositive. Despite evidence of CAV infection in wolves, none of the dogs sampled in the park were CAV seropositive, although this virus appeared highly seroprevalent and endemic in urban dogs. All dogs tested for CPV antibodies were seropositive. The BMNP wolf population declined in the late 1980s and early 1990s, with rabies responsible for a dramatic population reduction between 1990 and 1992. Although the population declined further up until 1995, it is not possible to assess whether the concurrent canine distemper epidemic in park dogs also affected wolves. Nevertheless, with evidence of rabies, CDV, CAV and CPV infections in sympatric domestic dogs and Ethiopian wolves, canid diseases clearly pose a significant threat to the future persistence of this Ethiopian wolf population.

Comparison of selected canine vaccines for their ability to induce protective immunity against canine parvovirus infection

Abstract Objective To compare the ability of 6 commercially available multicomponent canine vaccines to stimulate antibody production in pups with variable amounts of maternally derived canine parvovirus (CPV) antibody and to induce protective immunity against challenge exposure. Animals Sixty-three 5- to 6-week-old Beagle pups with passively acquired CPV antibody titer between 1:20 and 1:320. Procedure 9 pups were assigned to each of 6 vaccine groups and 1 control group. Eight pups in each group were inoculated with vaccine or saline solution twice, with 3 weeks between administrations. The ninth pup served as an uninoculated contact control. Serum samples were obtained weekly and tested for CPV antibody by hemagglutination-inhibition assay. All pups were challenge exposed with virulent CPV-2a and CPV-2b at 14 to 15 weeks of age. Results 3 of the vaccines failed to provide protective immunity against challenge exposure because all pups in these groups became infected and most died. A fourth vaccine protected against death, but not infection and disease. Two of the 6 vaccines induced an immune response that was protective against infection and disease. Conclusion and Clinical Relevance Substantial differences existed among commercial vaccines available in 1994 in their ability to immunize pups with maternally derived CPV antibody. These differences caused many vaccinated pups to be susceptible to CPV disease for variable periods because some vaccines failed to immunize. Importantly, all 4 of the vaccines that performed poorly have recently been replaced by more effective products so that the 6 vaccines now perform similarly. (Am J Vet Res 1997;58: 360-363)

Assessment of maternal antibody decay and response to canine parvovirus vaccination using a clinic-based enzyme-linked immunosorbent assay.

Interference caused by maternal antibodies is considered a major cause of canine parvovirus (CPV) vaccination failure. In this study, an immunoblot clinic-based enzyme-linked immunosorbent assay (ELISA) method was used to detect CPV antibodies in sera of pregnant bitches and their offspring to study the response of pups to vaccination. With a easily accessible procedure for CPV antibody determination, the veterinarian should be able to gauge the response of pups after vaccination. The validity of the technique was tested in parallel against the standard hemagglutination inhibition (HI) test. Results of the ELISA were correlated with those of the standard HI method for quantification of CPV antibodies. With the ELISA, successfully immunized pups were identified, allowing for a more reliable and cost-effective program of vaccination. This simple clinic-based test could be used for the assessment of vaccination status of pups during the critical phase of 6 to about 16 weeks of age. This study is the first in which vaccination response to CPV in pups was followed, using a clinic-based ELISA for CPV antibody monitoring.

Effects of Canine Parvovirus on Gray Wolves in Minnesota

Long-term effects of disease on wild animal population demography is not well documented. We studied a gray wolf (Canis lupus population in a 2,060-km 2 area of Minnesota for 15 years to determine its response to canine parvovirus (CPV). The CPV had little effect (P > 0.05) on wolf population size while epizootic during 1979-83. However, after CPV became enzootic, percentage of pups captured during summerfall 1984-93 and changes in subsequent winter wolf numbers were each inversely related to the serological prevalence of CPV in wolves captured during July-November (r 2 = 0.39 and 0.72, P = 0.05 and < 0.01, respectively). The CPV antibody prevalence in adult wolves increased to 87% in 1993 (r 2 = 0.28, P = 0.05). However, because population level remained stable, CPV-induced mortality appeared to compensate for other mortality factors such as starvation. We predict that the winter wolf population will decline when CPV prevalence in adults consistently exceeds 76%. The CPV may become important in limiting wolf populations.

SEROLOGIC RESPONSE OF CAPTIVE COYOTES (CANIS LATRANS SAY) TO CANINE PARVOVIRUS AND ACCOMPANYING PROFILES OF CANINE CORONAVIRUS TITERS

Fifty-five of 66 (83%) coyote pups from bitches vaccinated against canine parvovirus (CPV) were seropositive for CPV antibodies at birth. The CPV antibody titer in the pups declined with a half-life of 6.7 days until by the 8th week, only two of 41 (5%) pups were seropositive for CPV antibodies. At 8 wk, 41 of the pups were vaccinated against CPV (killed feline origin vaccine), but only one of 37 (3%) was positive for CPV antibodies at 11 wk. The 8-wk-old pups were either too young to respond to the CPV vaccine; they had sufficient undetectable, maternally-derived CPV antibodies to block active immunization; 3 wk was not a sufficient time for an immunological response from the pups; or the vaccine was poorly antigenic. Twenty of the 66 pups (30%) were seropositive for canine coronavirus (CCV) antibodies at birth, and all but three of the 20 were whelped from bitches that were also seropositive for CCV antibodies. Vaccination of females prior to whelping appeared to provide protection to their pups from CPV-induced mortality.